Regeneron and Roche Await Data On Potential COVID-19 Blockbuster
Early Signs Of Efficacy Expected In September
Results from COVID-19 antibody therapies from Regeneron and Lilly and several other developers are expected soon – but their window of opportunity could be short.
You may also be interested in...
Single neutralizing antibody moves to US FDA with data showing reduced hospitalization, while Lilly’s EUA filing for two-antibody combo awaits safety data and more certainty about production capabilities.
Following last month’s data showing reduced hospitalization risk with single neutralizing antibody therapy, Lilly now has data showing a two-antibody combo reduces COVID-19 viral load significantly.
Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.